CHRS
Price
$1.65
Change
-$0.06 (-3.51%)
Updated
Oct 17 closing price
Capitalization
191.78M
23 days until earnings call
OGEN
Price
$1.26
Change
-$0.04 (-3.08%)
Updated
Oct 17 closing price
Capitalization
5.2M
Interact to see
Advertisement

CHRS vs OGEN

Header iconCHRS vs OGEN Comparison
Open Charts CHRS vs OGENBanner chart's image
Coherus Oncology
Price$1.65
Change-$0.06 (-3.51%)
Volume$839.87K
Capitalization191.78M
Oragenics
Price$1.26
Change-$0.04 (-3.08%)
Volume$66.51K
Capitalization5.2M
CHRS vs OGEN Comparison Chart in %
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. OGEN commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and OGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (CHRS: $1.65 vs. OGEN: $1.26)
Brand notoriety: CHRS and OGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 65% vs. OGEN: 40%
Market capitalization -- CHRS: $191.78M vs. OGEN: $5.2M
CHRS [@Biotechnology] is valued at $191.78M. OGEN’s [@Biotechnology] market capitalization is $5.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileOGEN’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • OGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than OGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 3 TA indicator(s) are bullish while OGEN’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 3 bullish, 5 bearish.
  • OGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OGEN is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -1.20% price change this week, while OGEN (@Biotechnology) price change was -3.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($192M) has a higher market cap than OGEN($5.2M). CHRS YTD gains are higher at: 19.565 vs. OGEN (-88.627). CHRS has higher annual earnings (EBITDA): 88.2M vs. OGEN (-9.51M). CHRS has more cash in the bank: 238M vs. OGEN (1.97M). OGEN has less debt than CHRS: OGEN (3M) vs CHRS (41M). CHRS has higher revenues than OGEN: CHRS (272M) vs OGEN (0).
CHRSOGENCHRS / OGEN
Capitalization192M5.2M3,692%
EBITDA88.2M-9.51M-928%
Gain YTD19.565-88.627-22%
P/E Ratio3.11N/A-
Revenue272M0-
Total Cash238M1.97M12,057%
Total Debt41M3M1,367%
FUNDAMENTALS RATINGS
CHRS vs OGEN: Fundamental Ratings
CHRS
OGEN
OUTLOOK RATING
1..100
8085
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5100
PRICE GROWTH RATING
1..100
3791
P/E GROWTH RATING
1..100
80100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (37) in the Biotechnology industry is in the same range as OGEN (47). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OGEN (100). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

CHRS's SMR Rating (5) in the Biotechnology industry is significantly better than the same rating for OGEN (100). This means that CHRS’s stock grew significantly faster than OGEN’s over the last 12 months.

CHRS's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for OGEN (91). This means that CHRS’s stock grew somewhat faster than OGEN’s over the last 12 months.

CHRS's P/E Growth Rating (80) in the Biotechnology industry is in the same range as OGEN (100). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSOGEN
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 10 days ago
74%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FRPH25.270.46
+1.85%
FRP Holdings
NXT87.06-0.52
-0.59%
Nextracker
VSH16.49-0.43
-2.54%
Vishay Intertechnology
BENF0.52-0.03
-4.73%
Beneficient
LINK8.92-0.68
-7.08%
Interlink Electronics

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-3.51%
XENE - CHRS
40%
Loosely correlated
-1.28%
ADCT - CHRS
39%
Loosely correlated
-1.21%
ARRY - CHRS
39%
Loosely correlated
-0.17%
AXON - CHRS
38%
Loosely correlated
+2.84%
XNCR - CHRS
36%
Loosely correlated
-1.20%
More

OGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGEN has been loosely correlated with GOVX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if OGEN jumps, then GOVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGEN
1D Price
Change %
OGEN100%
-3.08%
GOVX - OGEN
36%
Loosely correlated
-1.71%
ATHA - OGEN
35%
Loosely correlated
-1.09%
REVB - OGEN
34%
Loosely correlated
-3.01%
SRPT - OGEN
30%
Poorly correlated
-3.56%
CHRS - OGEN
27%
Poorly correlated
-3.51%
More